echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Amgen/AstraZeneca first in class TSLP inhibitor approved by FDA for marketing

    Amgen/AstraZeneca first in class TSLP inhibitor approved by FDA for marketing

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 17, AstraZeneca and Amgen announced that the US FDA has approved the listing of Tezspire (tezepelumab-ekko) for the additional maintenance treatment of children and adults with severe asthma 12 years of age and older


    Thymus stromal lymphopoietin (TSLP) is a key epithelial cytokine, located at the top of multiple inflammatory cascades, and triggers an excessive immune response to airway inflammation related to severe asthma such as allergies and eosinophils


    Tezepelumab is a first-in-class human monoclonal antibody that prevents immune cells from releasing pro-inflammatory cytokines by blocking TSLP, thereby preventing asthma attacks and improving asthma control


    This marketing application is supported by data from a key phase III clinical study code-named NAVIGATOR, which evaluated the efficacy and safety of tezepelumab + standard therapy (SoC) vs.


    At 52 weeks of treatment, compared with placebo, patients in the tezepelumab group had a statistically and clinically significant reduction in AAER


    In 2020, Amgen and AstraZeneca updated the 2012 cooperation agreement on tezepelumab


    There are about 2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.